Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 23, 2019

View Archived Issues

Novel mouse models of chronic sustained hypoxia and chronic intermittent hypoxia

OP-1250 shrinks ER-positive breast tumors in xenograft models

Vaccitech Oncology collaborates with Cancer Research UK on phase I/IIa study of VTP-600 vaccine

Zentalis begins phase I/II trial of DDR drug candidate ZN-c3

Genistein analogue AXP-107-11 acts as chemoenhancer in pancreatic ductal adenocarcinoma

Lack of clinical effect with AVL-3288 in phase Ib trial in schizophrenia patients

Freeline Therapeutics describes novel next-generation AAV-hFVIII vector candidate

Microbiome-based therapies may be useful against ALDs

Ryaltris receives marketing approval in Australia

'Aggrephagy' is viral immune evasion mechanism

Jiangsu Vcare Pharmatech describes new EGFR inhibitors

New cannabinoid CB1/2 receptor ligands discovered at AL&AM Pharmachem

Shionogi presents new histone deacetylase inhibitors

Merck & Co. patents HIV integrase inhibitors

New protein cereblon ligands identified at C4 Therapeutics

FDA approves Dayvigo for insomnia

Orkedia approved in Japan for hypercalcemia in parathyroid carcinoma or primary hyperparathyroidism

FDA approves Enhertu for unresectable or metastatic HER2-positive breast cancer

Quantum Genomics begins phase III study of firibastat in hypertension

New INDUCE-3 trial studies GSK-3359609 and pembrolizumab for PD-L1-positive HNSCC

FDA issues complete response letter for long-acting cabotegravir/rilpivirine regimen for HIV

InxMed gains clearance in China for phase I trial of IN-10018

Popular Stories

News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
Roche identifies new TREM2 agonists
BioWorld Science
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...
Plasticity, properly parsed, provides psychiatric platform
BioWorld
If Benjamin Braddock, of The Graduate fame, were a young neuroscientist in the 21st century instead of a liberal arts graduate in 1967, the advice he received...